How Can “Smart Beta” Go Horribly Right?

Key Points

  • Since its rise to popularity nearly a decade ago, “smart beta” investing has gone horribly wrong relative to expectations.

  • Our early 2017 valuation-based forecasts for smart beta strategies, while correlated with realized performance, turned out to not be pessimistic enough.

  • Almost every strategy we analyzed experienced underperformance and decreasing relative valuations vs. the market portfolio and its large allocation to Magnificent Seven stocks.

  • Our current forecasts of smart beta returns paint a very different picture—we expect nearly every investing style featured here to outperform.

In our February 2016 article, “How Can ‘Smart Beta’ Go Horribly Wrong,” we warned that the burgeoning landscape of factor-based systematic equity strategies might turn out to be more desert than oasis, more dust bowl than bread basket. “Mean reversion could wreak havoc in the world of smart beta,” we wrote. “Many practitioners and their clients will not feel particularly ‘smart’ if this forecast comes to pass.”

At the time, these practitioners were promising the world—exposure to equity markets plus additional excess returns from well-known and well-vetted sources of factor premia—all in low-fee, index-like products. Our advice to investors was simple: Manage your expectations. Rosy simulations of investment styles that would have done well in the past rarely account for a potential source of that outperformance: rising valuations.

rosy simulations

If a smart beta strategy beats the market by 2% per year for 20 years but its valuation relative to the market also rises by 2% per year, what does that imply about that strategy’s future alpha potential? In our view, it indicates that continued outperformance is unlikely, maybe even impossible. Why? Because no strategy can grow more expensive relative to the market portfolio ad infinitum. At best, we’d expect this source of “premium” not to generate any excess returns going forward. At worst, we’d anticipate that the strategy is now overpriced and that mean-reverting valuations will lead to negative relative performance in the future.

That was how “smart beta” could go horribly wrong.